Today: 7 February 2026
Subscribe
Browse Category

NYSE:KMB News 3 November 2025 - 25 December 2025

Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

U.S. markets are closed for Christmas Day (December 25, 2025), but investors aren’t exactly “off the clock” when it comes to Kenvue Inc. (NYSE: KVUE). The former Johnson & Johnson consumer-health spinout has become a live merger-arbitrage story after Kimberly-Clark agreed to buy it, and KVUE’s price action is now a referendum on deal timing, legal risk, and whether the takeover terms hold up through 2026. As of the most recent close (Wednesday, December 24), KVUE finished at $17.21, up 1.12%, with ~14.1 million shares traded—well below its recent average volume. MarketWatch Below is what’s on the tape for December
25 December 2025
······
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Inc. (NYSE: KVUE) is trading in a very particular kind of gravity field on December 23, 2025: part consumer-health staple, part legal-headline lightning rod, and—most importantly right now—part merger-arbitrage instrument because of its pending acquisition by Kimberly-Clark. As of the latest U.S. session data available Tuesday, KVUE traded around $16.98, while Kimberly-Clark (NYSE: KMB) traded around $99.97. That matters because Kenvue shareholders are set to receive $3.50 in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share at closing, under the announced transaction terms. Kenvue Investors This structure turns KVUE into a living spreadsheet cell: every $1 move
23 December 2025
·······
Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Inc. (NYSE: KVUE) — the consumer-health company behind Tylenol, Band-Aid, Listerine, Aveeno, and Neutrogena — is trading in a very particular kind of market right now: not just “up or down,” but “how likely is the Kimberly-Clark deal to close, and what’s the risk premium?” As of Dec. 19, 2025 (19.12.2025), KVUE last traded around $17.10. That comes right after Thursday’s close at $17.10, when the stock fell 1.04% and saw elevated trading volume, according to MarketWatch. marketwatch.com What’s moving Kenvue stock on Dec. 19, 2025 Three forces dominate the current KVUE narrative: The deal that matters: Kimberly-Clark’s acquisition
19 December 2025
······
Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Inc. (NYSE: KVUE)—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a deal that has put a very visible “price anchor” on KVUE… while lawsuits, regulatory steps, and the calendar to closing keep the stock from simply snapping to the offer value. investors.kenvue.com+2Reuters+2 Below is what matters for KVUE as of Monday, December 15, 2025: where the stock is trading, what the Kimberly-Clark deal implies, the newest filings and headlines hitting screens
15 December 2025
······
KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

Published: November 22, 2025 — Information only, not investment advice. KVUE stock price today: trading below deal value but off the lows Kenvue Inc. (NYSE: KVUE) — the consumer health company behind Tylenol, Band‑Aid, Neutrogena and Listerine — is back in focus this weekend after another strong session on Friday. As of the most recent quote in late Friday trading (00:15 UTC on Saturday, November 22), KVUE last changed hands around $16.64, up roughly 3% on the day, with heavy volume of about 47 million shares. That move comes on top of a roughly 17% jump earlier this month when
22 November 2025
····
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Stock Price and Intraday Performance (Nov 3, 2025) Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday Reuters. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 Stockanalysis, near its 52-week low of ~$14.02 Reuters Reuters. The takeover premium (deal valued at ~$21.01 per share) immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement (KMB shares fell ~12.5% on
3 November 2025
······
1 2 3

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 1:01 AM EST Crude Oil Prices Rise on Dollar Weakness, Geopolitical Tensions February 7, 2026, 12:52 AM EST. Crude oil prices edged higher on Friday, supported by a weaker U.S. dollar and escalating geopolitical risks in the Middle East. March WTI crude gained 0.41%, rebounding from early losses, while gasoline prices rose 1.38%. Doubts over a U.S.-Iran nuclear deal loom after reports of Iran's refusal to halt uranium enrichment, raising the risk of military action and potential disruption of vital shipping routes. Additionally, a surge in U.S. consumer
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop